{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T10:40:51Z","timestamp":1777977651501,"version":"3.51.4"},"reference-count":74,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,8,15]]},"DOI":"10.2169\/internalmedicine.4275-19","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T22:05:54Z","timestamp":1588889154000},"page":"2015-2021","source":"Crossref","is-referenced-by-count":16,"title":["Systemic Sarcoidosis Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis: A Case Report and Review of the Literature"],"prefix":"10.2169","volume":"59","author":[{"given":"Keigo","family":"Koda","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Hamamatsu Rosai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikio","family":"Toyoshima","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hamamatsu Rosai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Nozue","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hamamatsu Rosai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Hamamatsu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Patterson KC, Chen ES. The pathogenesis of pulmonary sarcoidosis and implications for treatment. Chest 53: 1432-1442, 2018.","DOI":"10.1016\/j.chest.2017.11.030"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ungprasert P, Ryu JH, Matteson EL. Clinical manifestations, diagnosis, and treatment of sarcoidosis. Mayo Clin Proc Innov Qual Outcomes 3: 358-375, 2019.","DOI":"10.1016\/j.mayocpiqo.2019.04.006"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Peno-Green L, Lluberas G, Kingsley T, Brantley S. Lung injury linked to etanercept therapy. Chest 122: 1858-1860, 2002.","DOI":"10.1378\/chest.122.5.1858"},{"key":"4","unstructured":"4. Hashkes PJ, Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol 21: 645-646, 2003."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gonz\u00e1lez-L\u00f3pez MA, Blanco R, Gonz\u00e1lez-Vela MC, Fern\u00e1ndez-Llaca H, Rodr\u00edguez-Valverde V. Development of sarcoidosis during etanercept therapy. Arthritis Rheum 55: 817-820, 2006.","DOI":"10.1002\/art.22238"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. O'Shea FD, Marras TK, Inman RD. Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum 55: 978-981, 2006.","DOI":"10.1002\/art.22351"},{"key":"7","unstructured":"7. Almod\u00f3var R, Izquierdo M, Zarco P, Javier Quir\u00f3s F, Mazzucchelli R, Steen B. Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 25: 99-101, 2007."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Bachmeyer C, Blum L, Petitjean B, Kemiche F, Pertuiset E. Granulomatous tattoo reaction in a patient treated with etanercept. J Eur Acad Dermatol Venereol 21: 550-552, 2007.","DOI":"10.1111\/j.1468-3083.2006.01949.x"},{"key":"9","unstructured":"9. Kudrin A, Chilvers ER, Ginawi A, et al. Sarcoid-like granulomatous disease following etanercept treatment for RA. J Rheumatol 34: 648-649, 2007."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Farah RE, Shay MD. Pulmonary sarcoidosis associated with etanercept therapy. Pharmacotherapy 10: 1446-1448, 2007.","DOI":"10.1592\/phco.27.10.1446"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol 26: 1969-1971, 2007.","DOI":"10.1007\/s10067-007-0594-1"},{"key":"12","unstructured":"12. Sturfelt G, Christensson B, Bynke G, Saxne T. Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab. J Rheumatol 34: 2313-2314, 2007."},{"key":"13","unstructured":"13. Toussirot E, Pertuiset E, Kantelip B, Wendling D. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol 26: 471-475, 2008."},{"key":"14","unstructured":"14. Dubosc AE, Perroud AM, Bagot M, et al. Cutaneous granulomas during infliximab therapy for spondyloarthropathy. J Rheumatol 35: 1222-1223, 2008."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ishiguro T, Takayanagi N, Kurashima K, et al. Development of sarcoidosis during etanercept therapy. Intern Med 47: 1021-1025, 2008.","DOI":"10.2169\/internalmedicine.47.0602"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Metyas SK, Tadros RM, Arkfeld DG. Adalimumab-induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis. Rheumatol Int 29: 437-439, 2009.","DOI":"10.1007\/s00296-008-0691-8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Suzuki J, Goto H. Uveitis associated with sarcoidosis exacerbated by etanercept therapy. Jpn J Ophthalmol 53: 439-440, 2009.","DOI":"10.1007\/s10384-009-0691-6"},{"key":"18","unstructured":"18. Da\u00efen CI, Monnier A, Claudepierre P, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 48: 883-886, 2009."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Samimi M, Lorette G, Machet L, de Muret A, Watier H, Maruani A. Facial granulomatous nodules during etanercept treatment for psoriasis. Int J Dermatol 48: 1025-1027, 2009.","DOI":"10.1111\/j.1365-4632.2009.04080.x"},{"key":"20","unstructured":"20. van der Stoep D, Braunstahl GJ, van Zeben J, Wouters J. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge. J Rheumatol 36: 2847-2848, 2009."},{"key":"21","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jbspin.2009.02.003","volume":"76","author":"S Josse","year":"2009","unstructured":"21. Josse S, Klemmer N, Moreno-Swirc S, Go\u00ebb V, Lequerr\u00e9 T, Vittecoq O. Infliximab induced skin and pulmonary sarcoidosis in a rheumatoid arthritis patient. Joint Bone Spine 76: 718-719, 2009.","journal-title":"Joint Bone Spine","ISSN":"https:\/\/id.crossref.org\/issn\/1297-319X","issn-type":"print"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Takatori S, Kamata Y, Murosaki T, Iwamoto M, Minota S. Abrupt development of sarcoidosis with a prodromal increase in plasma osteopontin in a patient with rheumatoid arthritis during treatment with etanercept. J Rheumatol 37: 210-211, 2010.","DOI":"10.3899\/jrheum.090647"},{"key":"23","unstructured":"23. Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum 39: 313-319, 2010."},{"key":"24","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000275676","volume":"220","author":"F Dhaille","year":"2010","unstructured":"24. Dhaille F, Viseux V, Caudron A, et al. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases. Dermatology 220: 234-237, 2010.","journal-title":"Dermatology","ISSN":"https:\/\/id.crossref.org\/issn\/1018-8665","issn-type":"print"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Takahashi H, Kaneta K, Honma M, et al. Sarcoidosis during infliximab therapy for Crohn's disease. J Dermatol 37: 471-474, 2010.","DOI":"10.1111\/j.1346-8138.2010.00861.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Clementine RR, Lyman J, Zakem J, Mallepalli J, Lindsey S, Quinet R. Tumor necrosis factor-alpha antagonist-induced sarcoidosis. J Clin Rheumatol 16: 274-279, 2010.","DOI":"10.1097\/RHU.0b013e3181efa190"},{"key":"27","unstructured":"27. Pink AE, Fonia A, Smith CH, Barker JN. The development of sarcoidosis on antitumour necrosis factor therapy: a paradox. Br J Dermatol 163: 648-649, 2010."},{"key":"28","unstructured":"28. Cuchacovich R, Hagan J, Khan T, Richert A, Espinoa LR. Tumor necrosis factor-alpha (TNF-\u03b1)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature. Clin Rheumatol 30: 133-137, 2011."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Kanellopoulou T, Filiotou A, Kranidioti H, Dourakis SP. Sarcoid-like granulomatosis in patients treated with anti-TNF\u03b1 factors. A case report and review of the literature. Clin Rheumatol 30: 581-583, 2011.","DOI":"10.1007\/s10067-010-1603-3"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Salvatierra J, Magro-Checa C, Rosales-Alexander JL, Raya-Alvarez E. Acute sarcoidosis as parotid fever in rheumatoid arthritis under anti-tumor necrosis factor-alpha therapy. Rheumatology (Oxford) 50: 1346-1348, 2011.","DOI":"10.1093\/rheumatology\/ker166"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Haroon M, Ryan JG, Harney S. Development of sarcoidosis 6-month post discontinuation of etanercept: coincidence or real association? Clin Rheumatol 30: 1095-1098, 2011.","DOI":"10.1007\/s10067-011-1704-7"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Marcella S, Welsh B, Foley P. Development of sarcoidosis during adalimumab therapy for chronic plaque psoriasis. Australas J Dermatol 52: e8-e11, 2011.","DOI":"10.1111\/j.1440-0960.2010.00660.x"},{"key":"33","unstructured":"33. Tong D, Manolios N, Howe G, Spencer D. New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognized complication. Intern Med J 42: 89-94, 2012."},{"key":"34","unstructured":"34. Fonollosa A, Artaraz J, Les I, et al. Sarcoid intermediate uveitis following etanercept treatment: a case report and review of the literature. Ocul Immunol Inflamm 20: 44-48, 2012."},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Seve P, Varron L, Broussolle C, Denis P, Kodjikian L. Sarcoid-related uveitis occurring during adalimumab therapy. Ocul Immunol Inflamm 20: 59-60, 2012.","DOI":"10.3109\/09273948.2011.623213"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Burns AM, Green PJ, Pasternak S. Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab. J Cutan Pathol 39: 289-293, 2012.","DOI":"10.1111\/j.1600-0560.2011.01795.x"},{"key":"37","unstructured":"37. Skoie IM, Wildhagen K, Omdal R. Development of sarcoidosis following etanercept treatment: a report of three cases. Rheumatol Int 32: 1049-1053, 2012."},{"key":"38","unstructured":"38. Cathcart S, Sami N, Elewski B. Sarcoidosis as an adverse effect of tumor necrosis factor inhibitors. J Drugs Dermatol 11: 609-612, 2012."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Fok KC, Ng WW, Henderson CJ, Connor SJ. Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab. J Crohns Colitis 6: 708-712, 2012.","DOI":"10.1016\/j.crohns.2012.01.008"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Lamrock E, Brown P. Development of cutaneous sarcoidosis during treatment with tumour necrosis alpha factor antagonists. Australas J Dermatol 53: e87-e90, 2012.","DOI":"10.1111\/j.1440-0960.2011.00863.x"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Bhamra K, Stevens R. Pulmonary sarcoidosis following etanercept treatment. Case Rep Rheumatol 2012: 724013, 2012.","DOI":"10.1155\/2012\/724013"},{"key":"42","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jbspin.2012.05.001","volume":"80","author":"C Vigne","year":"2013","unstructured":"42. Vigne C, Tebib JG, Pacheco Y, Coury F. Sarcoidosis: an underestimated and potentially severe side effect of anti-TNF-alpha therapy. Joint Bone Spine 80: 104-107, 2013.","journal-title":"Joint Bone Spine","ISSN":"https:\/\/id.crossref.org\/issn\/1297-319X","issn-type":"print"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Mao-Draayer Y, Cash T. Neurosarcoidosis in a patient treated with tumor necrosis factor alpha inhibitors. J Neurol 260: 651-653, 2013.","DOI":"10.1007\/s00415-012-6726-9"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Christoforidou A, Goudakos J, Bobos M, Lefkaditis E, Vital V, Markou K. Sarcoidosis-like granulomatosis of the hypopharynx as a complication of anti-TNF therapy. Am J Otolaryngol 34: 268-272, 2013.","DOI":"10.1016\/j.amjoto.2012.12.016"},{"key":"45","unstructured":"45. Dragnev D, Barr D, Kulshrestha M, Shanmugalingam S. Sarcoid panuveitis associated with etanercept treatment, resolving with adalimumab. BMJ Case. Rep Forthcoming."},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Bhargava S, Perlman DM, Allen TL, Ritter JH, Bhargava M. Adalimumab induced pulmonary sarcoid reaction. Respir Med Case Rep 10: 53-55, 2013.","DOI":"10.1016\/j.rmcr.2013.07.002"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Santos G, Sousa LE, Jo\u00e3o AM. Exacerbation of recalcitrant cutaneous sarcoidosis with adalimumab-a paradoxical effect? A case report. An Bras Dermatol 88: 26-28, 2013.","DOI":"10.1590\/abd1806-4841.20132487"},{"key":"48","unstructured":"48. Unterstell N, Bressan AL, Serpa LA, Fonseca e Castro PP, Gripp AC. Systemic sarcoidosis induced by etanercept: first Brazilian case report. An Bras Dermatol 88: 197-199, 2013."},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Durel CA, Feurer E, Pialat JB, Berthoux E, Chapurlat RD, Confavreux CB. Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis. BMC Neurol 13: 212, 2013.","DOI":"10.1186\/1471-2377-13-212"},{"key":"50","unstructured":"50. Kotze PG, de Barcelos IF, da Silva Kotze LM. Sarcoidosis during therapy with adalimumab in a Crohn's disease patient: a paradoxical effect. J Crohns Colitis 7: e599-e600, 2013."},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Alhajri M, Aljumaah S, Aleyouni Y, Al-Qahtani F, Alhazzaa S, Al-Mayouf SM. Granulomatous disease in a child treated with etanercept. Int J Rheum Dis 16: 472-474, 2013.","DOI":"10.1111\/1756-185X.12078"},{"key":"52","unstructured":"52. Moisseiev E, Shulman S. Certolizumab-induced uveitis: a case report and review of the literature. Case Rep Ophthalmol 5: 54-59, 2014."},{"key":"53","unstructured":"53. Chaowattanapanit S, Aiempanakit K, Silpa-Archa N. Etanercept-induced sarcoidosis presented with scrotal lesion: a rare manifestation in genital area. J Dermatol 41: 267-268, 2014."},{"key":"54","unstructured":"54. Au S, Mirsaeidi M, Aronson IK, Sweiss NJ. Adalimumab induced subcutaneous nodular sarcoidosis; a rare side effect of tumor necrosis factor-\u03b1 inhibitor. Sarcoidosis Vasc Diffuse Lung Dis 31: 249-251, 2014."},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Miyagi R, Ideguchi H, Soga T, et al. Development of pulmonary and cardiac sarcoidosis during etanercept therapy. Int J Rheum Dis 17: 810-812, 2014.","DOI":"10.1111\/1756-185X.12178"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. McDonnell MJ, Rutherford RM, O'Regan A. Sarcoidosis complicating treatment with adalimumab for Crohn's disease. J Crohns Colitis 8: 1140-1141, 2014.","DOI":"10.1016\/j.crohns.2014.02.006"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Villemaire M, Cartier JC, Mathieu N, et al. Renal sarcoid-like granulomatosis during anti-TNF therapy. Kidney Int 86: 215, 2014.","DOI":"10.1038\/ki.2013.452"},{"key":"58","unstructured":"58. Korta DZ, Ochieng P, Fishman D, Katz SE. Pulmonary sarcoidosis and latent tuberculosis in a patient with psoriasis treated with adalimumab. Dermatol Online J. Forthcoming."},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Baha A, Hanazay C, Kokturk N, Turktas H. A case of sarcoidosis associated with anti-tumor necrosis factor treatment. J Investig Med High Impact Case Rep 3: 2324709615571366, 2015.","DOI":"10.1177\/2324709615571366"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Simonetto DA, Papadakis KA. New-onset paresthesias in inflammatory bowel disease. Gastroenterology 148: 906-907, 2015.","DOI":"10.1053\/j.gastro.2014.12.040"},{"key":"61","unstructured":"61. Akiyama M, Kaneko Y, Hanaoka H, Kuwana M, Takeuchi T. Acute kidney injury due to renal sarcoidosis during etanercept therapy: a case report and literature review. Intern Med 54: 1131-1134, 2015."},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Berrios I, Jun-O'Connell A, Ghiran S, Ionete C. A case of neurosarcoidosis secondary to treatment of etanercept and review of the literature. BMJ Case Rep. 2015.","DOI":"10.1136\/bcr-2014-208188"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Vieira MA, Saraiva MI, Silva LK, Fraga RC, Kakizaki P, Valente NY. Development of exclusively cutaneous sarcoidosis in patient with rheumatoid arthritis during treatment with etanercept. Rev Assoc Med Bras (1992) 62: 718-720, Forthcoming.","DOI":"10.1590\/1806-9282.62.08.718"},{"key":"64","unstructured":"64. Mengi G, G\u00f6\u011f\u00fc\u015f F. A rare adverse effect of anti-tumor necrosis factor alpha therapy: sarcoidosis. Arch Rheumatol 32: 67-70, 2017."},{"key":"65","unstructured":"65. Park SK, Hwang PH, Yun SK, Kim HU, Park J. Tumor necrosis factor alpha blocker-induced erythrodermic sarcoidosis in with juvenile rheumatoid arthritis: a case report and review of the literature. Ann Dermatol 29: 74-78, 2017."},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Decock A, Van Assche G, Vermeire S, Wuyts W, Ferrante M. Sarcoidosis-like lesions: another paradoxical reaction to anti-TNF therapy? J Crohns Colitis 11: 378-383, 2017.","DOI":"10.1093\/ecco-jcc\/jjw155"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Sakai H, Nomura W, Sugawara M. Certolizumab pegol-induced folliculitis-like lichenoid sarcoidosis in a patient with rheumatoid arthritis. Case Rep Dermatol 9: 158-163, 2017.","DOI":"10.1159\/000477957"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Isshiki T, Matsuyama H, Sakamoto S, et al. Development of propionibacterium acnes-associated sarcoidosis during etanercept therapy. Intern Med 58: 1473-1477, 2019.","DOI":"10.2169\/internalmedicine.2086-18"},{"key":"69","doi-asserted-by":"publisher","unstructured":"69. Chopra A, Nautiyal A, Kalkanis A, Judson MA. Drug-induced sarcoidosis-like reactions. Chest 154: 664-677, 2018.","DOI":"10.1016\/j.chest.2018.03.056"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Vermeire S, Gils A, Accossato P, Lula S, Marre A. Immunogenicity of biologics in inflammatory bowel disease. Ther Adv Gastroenterol 11: 1-13, 2018.","DOI":"10.1177\/1756283X17750355"},{"key":"71","unstructured":"71. Shin JI, Kim DS. Development of sarcoidosis during anti-TNF-alpha treatment: what is the mechanism? Clin Exp Rheumatol 27: 1054, 2009."},{"key":"72","doi-asserted-by":"publisher","unstructured":"72. Shealy D, Kai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor \u03b1. mAbs 2: 428-439, 2010.","DOI":"10.4161\/mabs.12304"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Ramos-Casals M, Brito-Zer\u00f3n P, Mu\u00f1oz S, Soto M-J. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 87: 345-364, 2008.","DOI":"10.1097\/MD.0b013e318190f170"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Ramos-Casals M, Perez-Alvarez R, Diaz-Lagares C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 9: 188-193, 2010.","DOI":"10.1016\/j.autrev.2009.10.003"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/16\/59_4275-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T13:42:00Z","timestamp":1722865320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/16\/59_4275-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,15]]},"references-count":74,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4275-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,15]]}}}